These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23279038)

  • 1. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
    Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
    BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Schroeck FR; Jacobs BL; Bhayani SB; Nguyen PL; Penson D; Hu J
    Eur Urol; 2017 Nov; 72(5):712-735. PubMed ID: 28366513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
    Amin NP; Sher DJ; Konski AA
    Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service.
    Close A; Robertson C; Rushton S; Shirley M; Vale L; Ramsay C; Pickard R
    Eur Urol; 2013 Sep; 64(3):361-9. PubMed ID: 23498062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.
    Ramsay C; Pickard R; Robertson C; Close A; Vale L; Armstrong N; Barocas DA; Eden CG; Fraser C; Gurung T; Jenkinson D; Jia X; Lam TB; Mowatt G; Neal DE; Robinson MC; Royle J; Rushton SP; Sharma P; Shirley MD; Soomro N
    Health Technol Assess; 2012; 16(41):1-313. PubMed ID: 23127367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
    BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
    Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies.
    Muralidhar V; Nguyen PL
    Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
    Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
    J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
    Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
    Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robotic Surgical System for Radical Prostatectomy: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(11):1-172. PubMed ID: 28744334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.
    Eldefrawy A; Katkoori D; Abramowitz M; Soloway MS; Manoharan M
    Urol Oncol; 2013 Jul; 31(5):576-80. PubMed ID: 21616691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
    Parikh R; Sher DJ
    Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
    Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
    BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
    Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
    J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
    Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
    BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.